The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine

Cancers, in active Ieo 698 trials, 'door access to new cancer therapies'

The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine

Precision cancer medicine promises to tailor clinical decisions to patients using genomic information. Indeed, successes of drugs targeting genetic al…

From the lab to the clinic: developing the next generation of precision cancer therapies

Crick group leader Simon Boulton co-founded Artios in 2016, a spin-out from Cancer Research UK’s Commercial Partnerships, where he is now VP of Science Strategy. Artios develops cancer treatments that target DNA damage response pathways. Simon discusses how Artios was set up, their latest trial results and how to translate research from the lab into the clinic.